Log in

NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

$2.09
+0.04 (+1.95 %)
(As of 02/27/2020 06:12 AM ET)
Today's Range
$2.04
Now: $2.09
$2.11
50-Day Range
$2.05
MA: $2.70
$3.30
52-Week Range
$2.04
Now: $2.09
$3.82
Volume131,583 shs
Average Volume239,629 shs
Market Capitalization$201.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.15 per share

Profitability

Net Income$-27,470,000.00

Miscellaneous

Employees124
Market Cap$201.37 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.


CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The biotechnology company earned $2.79 million during the quarter, compared to analysts' expectations of $0.70 million. View CASI Pharmaceuticals' Earnings History.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for CASI Pharmaceuticals.

What price target have analysts set for CASI?

1 equities research analysts have issued 1 year price objectives for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they expect CASI Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 234.9% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.

What is the consensus analysts' recommendation for CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

Press coverage about CASI stock has trended neutral recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for CASI Pharmaceuticals.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,840,000 shares, a decline of 5.0% from the January 15th total of 2,990,000 shares. Based on an average daily trading volume, of 108,300 shares, the days-to-cover ratio is currently 26.2 days. Approximately 7.5% of the company's shares are sold short. View CASI Pharmaceuticals' Current Options Chain.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the folowing people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 54)
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
  • Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
  • Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include IDG Accel China Growth Fund III Associates L.P. (8.28%), Wellington Shields & Co. LLC (1.33%), State Street Corp (0.99%), Charles Schwab Investment Management Inc. (0.31%), California Public Employees Retirement System (0.13%) and Vident Investment Advisory LLC (0.07%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, China Growth Fund Idg-Accel II and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Bank of America Corp DE. View Insider Buying and Selling for CASI Pharmaceuticals.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was bought by a variety of institutional investors in the last quarter, including IDG Accel China Growth Fund III Associates L.P., Wellington Shields & Co. LLC, State Street Corp, Zebra Capital Management LLC, Charles Schwab Investment Management Inc., Barclays PLC, UBS Group AG and Vident Investment Advisory LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, China Growth Fund Idg-Accel II and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.09.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $201.37 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel